A study also demonstrated that the expression of IL-6 was increased in the lung, and IL-6 blockade by the monoclonal anti–IL-6 receptor antibody MR16-1 could ameliorate the pulmonary hypertension (PH) of pristane/hypoxia mice (a novel mouse model of PH reflecting the pathological features of CTD-PAH) (Mori et al., 2020). This evidence concerns the gene IL6 and pulmonary hypertension.